Zoetis Earnings Beat Estimates, Revenue Misses Expectations Despite Pet Healthcare Slowdown

Zoetis ZTS reported second-quarter 2026 adjusted earnings per share of $1.87, ahead of the $1.85 FactSet consensus and up from $1.78 a year earlier. Revenue came in roughly flat year over year at about $2.5 billion, missing analyst expectations, and the company cut its full-year 2026 outlook.

The disconnect matters because Zoetis is the largest pure-play animal health company, and the guidance cut signals the pet healthcare slowdown investors had been watching for has arrived. Management pointed to fewer clinic visits and heightened pet-owner price sensitivity as the drivers, alongside intensifying competition in key categories.

Zoetis now expects full-year adjusted EPS of $6.15-$6.25, down from its prior $6.85-$7.00 range, on revenue of $9.12-$9.32 billion, down from $9.68-$9.96 billion, with organic operational revenue seen declining 1% to 3%. The gap between a per-share earnings beat and a lowered top-line outlook is unusual and points to cost discipline offsetting softer demand rather than accelerating growth.

Analysts will be watching Zoetis' Q3 print for whether clinic visit trends stabilize, and whether the company's R&D pipeline and vaccine market position can cushion further demand softness. The scale of the cut suggests management sees the pet healthcare slowdown as more than a one-quarter blip.

Related Stocks

• ZTS
• FDS